Retrospective analysis of the renoprotective effects of long-term use of six types of sodium-glucose co-transporter 2 inhibitors in Japanese patients with type 2 diabetes mellitus and chronic kidney disease

AIM Sodium-glucose co-transporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2i in Japanese patients with T2DM and chronic kidney disease (CKD). MATERIALS AND METHODS The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved the clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for more than 1 year. RESULTS A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of the albumin-creatinine ratio (LNACR) decreased significantly from 1.60±0.65 to 1.51±0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change (Δ) in diastolic blood pressure, and ΔHbA1c were independently correlated with ΔLNACR (p 60 mL/min/1.73 m2. However, this was a retrospective observational study; further studies are needed to formulate final conclusions.